Chronic Sialorrhea Market Report 2026

The chronic sialorrhea market size has grown strongly in recent years. It will grow from $0.76 billion in 2025 to $0.81 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to increasing prevalence of neurological disorders, wider clinical use of anticholinergic medications, expansion of rehabilitation services, improved diagnosis of salivary disorders, growth in specialty clinic treatments.

The chronic sialorrhea market size is expected to see strong growth in the next few years. It will grow to $1.02 billion in 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to increasing approvals for new injectable therapies, rising focus on home-based care solutions, expansion of assistive oral devices, growing geriatric population, increasing investment in neurological disorder management. Major trends in the forecast period include increasing use of botulinum toxin therapies, rising adoption of non-invasive management approaches, growing focus on neurology-linked sialorrhea care, expansion of assistive medical devices, enhanced emphasis on quality-of-life improvement.

The increasing level of research and development activities is expected to drive the growth of the chronic sialorrhea market in the coming years. Research and development activities involve systematic efforts to create new innovations or enhance existing products, technologies, or processes through scientific research and experimentation. The rise in research and development is driven by the need for continuous innovation, enabling organizations to develop advanced solutions and remain competitive in evolving markets. In chronic sialorrhea, research and development efforts support the discovery and refinement of targeted therapies, delivery methods, and diagnostic approaches that more effectively reduce excessive drooling and improve patient quality of life. For instance, in 2023, according to the Office for National Statistics, a UK-based government agency, the UK government’s net spending on research and development increased to £17.4 billion ($22.1 billion) in 2023 from £16.1 billion ($20.45 billion) in 2022, reflecting an 8.2% increase. Therefore, the growth in research and development activities is contributing to the expansion of the chronic sialorrhea market.

The rising prevalence of neurodegenerative disorders is also expected to propel the growth of the chronic sialorrhea market going forward. Neurodegenerative disorders are a group of conditions characterized by the progressive degeneration or loss of nerve cells in the brain and spinal cord. The increasing incidence of these disorders is linked to factors such as genetic predisposition, family history, environmental influences, improved understanding of disease mechanisms, chronic health conditions, and social and psychological factors. Chronic sialorrhea is a common complication of neurodegenerative diseases such as Parkinson’s disease and amyotrophic lateral sclerosis, creating a need for targeted treatments to reduce aspiration risk, improve oral function, and enhance patient comfort. For example, in September 2023, according to Parkinson’s UK, a UK-based charitable organization, around 153,000 people in the UK were living with Parkinson’s disease, and this number is expected to rise by 20% to approximately 172,000 by 2030 due to an aging population. As a result, the growing prevalence of neurodegenerative disorders is driving the growth of the chronic sialorrhea market.

Major companies operating in the chronic sialorrhea market are focusing on the development of innovative and non-invasive treatments, such as oral solutions, to improve patient compliance, particularly among children. These approaches aim to enhance safety and effectiveness while minimizing side effects. An oral solution is a liquid medication designed for oral administration, in which the active ingredient is dissolved in a solvent to allow easy ingestion. For instance, in February 2023, Proveca Pharma Ltd., a UK-based pharmaceutical company, launched Sialanar (glycopyrronium bromide) in France for the treatment of severe chronic sialorrhea in children with neurological disorders. The product’s liquid formulation allows for easier administration and precise dosing, making it especially suitable for pediatric patients who have difficulty swallowing solid medications. It has a well-established safety and efficacy profile and helps improve quality of life by reducing excessive drooling, a common issue in neurodevelopmental conditions such as cerebral palsy.

Major companies operating in the chronic sialorrhea market are Pfizer Inc, Ipsen Pharmaceuticals Inc, Aurobindo Pharma Limited, Hugel Inc, Medy‑Tox Inc, Granules India Limited, US WorldMeds LLC, Merz Therapeutics GmbH, Taj Pharma India Limited, Teva Pharmaceutical Industries Ltd, Bayer AG, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Hikma Pharmaceuticals PLC, Lundbeck A/S, Sun Pharmaceutical Industries Ltd, AstraZeneca plc, Novartis AG, Astellas Pharma Inc, Viatris Inc, Sandoz International GmbH, Proveca Limited, NeuroHealing Pharmaceuticals Inc, Solstice Neurosciences Inc, Gufic Biosciences Limited.

North America was the largest region in the chronic sialorrhea market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic sialorrhea market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic sialorrhea market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the chronic sialorrhea market by increasing costs of imported botulinum toxin formulations, medical devices, injectable delivery systems, and pharmaceutical raw materials. North America and Europe are most affected due to reliance on specialized biologic imports, while Asia-Pacific faces cost challenges in device manufacturing. These tariffs are contributing to higher treatment expenses and access limitations. However, they are also supporting localized pharmaceutical production, regional device manufacturing, and innovation in cost-effective sialorrhea management solutions.

The chronic sialorrhea market research report is one of a series of new reports that provides chronic sialorrhea market statistics, including chronic sialorrhea industry global market size, regional shares, competitors with a chronic sialorrhea market share, detailed chronic sialorrhea market segments, market trends and opportunities, and any further data you may need to thrive in the chronic sialorrhea industry. This chronic sialorrhea market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chronic sialorrhea is defined as the ongoing excessive production of saliva or impaired control of salivation, and it is commonly associated with neurological disorders such as Parkinson’s disease, cerebral palsy, or amyotrophic lateral sclerosis. Management of the condition includes pharmacological therapies, botulinum toxin injections, or surgical procedures aimed at improving oral function, minimizing complications, and enhancing patients’ quality of life.

The primary treatment types for chronic sialorrhea include pharmacological therapies, botulinum toxin injections, surgical interventions, medical devices, and assistive therapies. Pharmacological management involves the use of medications such as anticholinergics and botulinum toxin injections to decrease excessive saliva production and control symptoms. These treatments are delivered through multiple routes, including oral medications, injectable therapies, and topical applications. The patient population receiving these treatments includes both pediatric and adult patients, with key end users comprising hospitals and specialty clinics, rehabilitation centers, and homecare settings.

The chronic sialorrhea market consists of revenues earned by entities by providing services such as medical treatment services, non-surgical interventions, and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic sialorrhea market also includes sales of neurostimulation devices, resection kits, absorbent clothing and bibs, and customized oral prosthetics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.